NCT06975124 taVNS Effects on Fear Ratings in Naturalistic Context
| NCT ID | NCT06975124 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | University of Electronic Science and Technology of China |
| Condition | Healthy Participants |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2025-03-01 |
| Primary Completion | 2025-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 70 participants in total. It began in 2025-03-01 with a primary completion date of 2025-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
During the fear rating task, 70 participants viewed a 600-second horror movie while continuously rating their subjective fear intensity (0-100 scale) every 0.51 seconds (1,170 total ratings). Functional near-infrared spectroscopy (fNIRS) data were simultaneously recorded using the NIRSIT LITE system to monitor cortical hemodynamic responses.
Eligibility Criteria
Inclusion Criteria: Healthy participants without color blindness, current or regular substance or medication use, any current or history of medical or psychiatric disorders and contraindications for MRI. Exclusion Criteria: * Color blindness, * Current or regular substance or medication use * any current or history of medical or psychiatric disorders and contraindications for MRI
Frequently Asked Questions
Who can join the NCT06975124 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 30 Years, studying Healthy Participants. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06975124 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06975124 currently recruiting?
Yes, NCT06975124 is actively recruiting participants. Visit ClinicalTrials.gov or contact University of Electronic Science and Technology of China to inquire about joining.
Where is the NCT06975124 trial being conducted?
This trial is being conducted at Chengdu, China.
Who is sponsoring the NCT06975124 clinical trial?
NCT06975124 is sponsored by University of Electronic Science and Technology of China. The trial plans to enroll 70 participants.